NCT03329950 2024-03-28
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Celldex Therapeutics
Phase 1 Completed
Celldex Therapeutics
Shanghai Simnova Biotechnology Co.,Ltd.
AbbVie
National Cancer Institute (NCI)